2019 Biotechnology Sector and Artificial Intelligence in Healthcare
Reporter: Aviva Lev-Ari, PhD, RN
3.3.9 2019 Biotechnology Sector and Artificial Intelligence in Healthcare, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair
AI Ushers in a New Era
The implications of AI, cloud-based technologies and increased R&D focus have lent a competitive edge to companies within the biotech space. The use of AI has gradually begun to revolutionize research activities in the industry as it can drastically reduce time and costs involved in developing life-saving drugs.
Let’s take a look at some instances on how AI is being used to advance in biotech. AiCure has developed an application that uses AI to govern if and at what time the patient takes a pill. Moreover, it is now being used regularly in many clinical trials. SOPHiA Genetics ‘ AI system is used for genomics analysis of next-generation sequencing data from hospitals and research institutions globally.
Moreover, Illumina ILMN released an open source artificial intelligence software for discovering previously overlooked noncoding mutations in patients with rare genetic diseases in the beginning of 2019.
In fact, J&J JNJ , Pfizer PFE and Novartis NVS have tie-ups with IBM’s Watson Health. Per the deals, the companies can use Watson Health’s AI solutions and applications for drug discovery and to accelerate cancer research efforts.
SOURCE
https://m.nasdaq.com/article/biotechnology-market-on-a-tear-5-etfs-in-spotlight-cm1128200
The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes reflects the same. In this context,
- the NASDAQ Biotechnology Index has returned 17.6% year to date. Following the trend,
- S&P Biotechnology Select Industry Index has returned around 29%.
SOURCE
https://m.nasdaq.com/article/biotechnology-market-on-a-tear-5-etfs-in-spotlight-cm1128200
BioPharma
Novartis AG (NVS): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
ALPS Medical Breakthroughs ETF (SBIO): ETF Research Reports
Principal Healthcare Innovators Index ETF (BTEC): ETF Research Reports
Virtus LifeSci Biotech Products ETF (BBP): ETF Research Reports
SPDR S&P Biotech ETF (XBI): ETF Research Reports
Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
ARK Genomic Revolution Multi-Sector ETF (ARKG): ETF Research Reports
SOURCE
To read this article on Zacks.com click here.
2019 M&A in Biotech
Mergers and acquisitions (M&As) are dominating the sector as sluggishness in mature products has forced companies to explore acquisitions to bolster their pipeline. The biggest deal of the year was Bristol-Myers’ acquisition offer of $74 billion to buy Celgene. Also, Eli Lilly and Company LLY has announced that it will take over Loxo Oncology for $8 billion to broaden its oncology suite to precision medicines or targeted therapies. (read: What’s Behind the Biotech ETF Rally to Start 2019? )
Several other large-cap pharma as well as bigger biotech companies are entering collaboration deals with smaller ones to boost their pipeline. Notably, Swiss pharma giant Roche Holdings RHHBY has bet big on U.S.-based gene therapy company Spark Therapeutics ONCE in an effort to strengthen its presence in gene therapy. Similarly, in order to develop gene therapies targeting rare indications, Biogen has offered to buy Nightstar Therapeutics.
Furthermore, in-licensing deals are consistently rising with bigwigs partnering with smaller and mid-sized players that own promising mid-to-late stage pipeline candidates or interesting technology.
SOURCE
https://m.nasdaq.com/article/biotechnology-market-on-a-tear-5-etfs-in-spotlight-cm1128200
Other related 260 articles published in this Open Access Online Scientific Journal include the following:
https://pharmaceuticalintelligence.com/?s=Artificial+Intelligence
To access 260 articles:
GO TO Categories
Select CATEGORY
Artificial Intelligence per Ontology on this topic [multiple nested categories]
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply